Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 11/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 11/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 9/20 | 0.33 |
| ▸ | CDK2 | P24941 | 9/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 9/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MGMT | P16455 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7809926 | 0.84 | TSHR (0.37) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL1025895 | 0.82 | CCNA2 (0.35) | CCNA2CDK2CCNA1 | |
| SCHEMBL7799942 | 0.79 | MGMT (0.50) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL8886045 | 0.78 | CDK1 (0.43) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL8883709 | 0.74 | MAPK8 (0.37) | LMNAALDH1A1KDM4E | |
| SCHEMBL536868 | 0.69 | — | — | |
| SCHEMBL536980 | 0.69 | DPP4 (0.34) | — | |
| SCHEMBL8884479 | 0.69 | — | — | |
| SCHEMBL16828155 | 0.67 | SMN1; SMN2 (0.40) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| Hydrochloric Acid SCHEMBL16828217 | 0.66 | SMN1; SMN2 (0.39) | CDK1CCNB1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180346505-A1 | MONONUCLEOTIDES HAVING A BIOREVERSIBLE DISULFIDE GROUP | SOLSTICE BIOLOGICS LTD (IE) | 2018-12-06 | — | — | US | disclosed |
| EP-3229815-A2 | MONONUCLEOTIDES HAVING A BIOREVERSIBLE DISULFIDE GROUP | Solstice Biologics, Ltd. (IE) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016094677-A2 | MONONUCLEOTIDES HAVING A BIOREVERSIBLE DISULFIDE GROUP | SOLSTICE BIOLOGICS, LTD. (IE) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346505-A1 | MONONUCLEOTIDES HAVING A BIOREVERSIBLE DISULFIDE GROUP | HCCS, PNP, NT5C3B | CDK1 916/4885CCNB1 939/4885CCNA2 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.